Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a prospective, single-arm, Phase II clinical study aimed at evaluating the efficacy and safety of 160mg fimonertinib in combination with definitive radiotherapy for patients with EGFR uncommon driver mutation-positive, Stage III unresectable lung adenocarcinoma. The primary endpoint is Progression-Free Survival (PFS), assessed by the investigator according to RECIST 1.1 criteria, defined as the time from the first dose to objective disease progression or death (from any cause). Secondary endpoints include PFS by different mutation types, OS, ORR, DCR, as well as adverse events and their severity.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony zaawansowany rak płuca (stadium III), który nie może być operacyjnie usunięty
- •Posiadanie rzadkiej mutacji genu EGFR (potwierdzonej badaniem genetycznym)
- •Nigdy wcześniej nie leczony chemioterapią lub radioterapią z powodu tego raka
- •Co najmniej jeden guz widoczny w badaniach obrazowych, którego wcześniej nie napromieniowywano
- •Dobry stan ogólny (możliwość wykonywania normalnych czynności)
- •Oczekiwana długość życia co najmniej 12 tygodni
- •Kobiety: ujemny test ciąży i skuteczna antykoncepcja lub potwierdzenie niemożliwości zajścia w ciążę
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 8, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Hunan Cancer Hospital
Changsha, China
Trial contact
Huai Liu
Xingxiang Pu
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.